Quantcast
Last updated on April 17, 2014 at 9:33 EDT

Latest Genentech Stories

2013-11-13 23:23:58

CHI & PwC to unveil life sciences jobs, revenue and industry impact report at Annual Meeting at Genentech, Nov. 21. La Jolla, CA (PRWEB) November 13, 2013 WHAT: California Healthcare Institute (CHI) is celebrating its 20th anniversary at its Annual Meeting at Genentech. Industry thought leaders will participate on panels discussing FDA regulatory policies, nurturing innovation in the face of sequestration and lack of venture capital (VC) investment, as well as highlight the patient...

2013-11-07 12:27:09

Interviewed Payers Indicate that Budget Constraints May Also Drive Uptake of Trastuzumab Biosimilars over Branded Herceptin, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed medical oncologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) currently prescribe Roche/Genentech's...

2013-11-07 04:24:12

THOUSAND OAKS, Calif., Nov. 7, 2013 /PRNewswire/ -- ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies. "ImmunGene, run by...

2013-10-31 23:29:18

ResearchMoz include new market research report "Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports. Click Here For Download Detail Report - http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html Albany, NY (PRWEB) October 31, 2013 Macular...

2013-10-28 08:30:29

Approval of Premium-Priced Novel Agents, Coupled With Rituximab's Continued Dominance, Will Drive a Robust Annual Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents--Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences'...

2013-10-24 08:34:16

Display Features Recently Acquired Objects from Genentech WASHINGTON, Oct. 24, 2013 /PRNewswire/ -- The Smithsonian's National Museum of American History chronicles the story of biotechnology and its impact on society in a new showcase display, "The Birth of Biotech," which opens Oct. 25. The display, located in a first floor History Highlights Case, will explore the science and industry behind the first major product of the biotech boom--recombinant human insulin. Made by...

2013-10-23 08:29:54

Boston Scientific, Genentech, and Merck Products Recognized for Contributions to the Human Condition NEW YORK, Oct. 23, 2013 /PRNewswire/ -- The Prix Galien USA Awards Committee last night honored excellence in research, development and innovation in the biopharmaceutical industry at its seventh annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. Led by Dr. P. Roy Vagelos, and comprised of an unrivaled network of nine esteemed individuals...

2013-10-17 23:29:14

Clinovo Supports Cancer Research in The Name of Peter Holthe on Friday October 18, 2013 at Poppy Ridge, CA (PRWEB) October 17, 2013 Clinovo sponsors the Genentech Golf Club 2013 Fall Classic, the annual Golf Tournament held at the Poppy Ridge Golf Course in Livermore, CA, on Friday October 18, 2013. Through this sponsorship, Clinovo proudly supports cancer research in the name of Peter Holthe. This year marks the fourth annual Genentech Charity Golf Tournament to support the fight against...

2013-10-17 08:30:27

Novartis's Lucentis Remains the Most Preferred Intravitreal Pharmacotherapy for Wet AMD Across the EU5, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 17, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, eight months after the approval of Bayer's Eylea for the treatment of wet age-related macular degeneration (AMD), nearly half of surveyed retinal...

2013-10-14 08:25:25

Prime Therapeutics analysis finds nearly 76 percent of patients taking Herceptin were treated in early stage breast cancer - important for predicting breast cancer future costs ST. PAUL, Minn., Oct. 14, 2013 /PRNewswire/ -- Expanded use of the common breast cancer drug HerceptinĀ® (trastuzumab) can be tracked using pharmacy and medical administrative claims data, according to a new analysis by pharmacy benefit manager Prime Therapeutics LLC (Prime). Prime will be presenting the study...